For the twelve months ended Sep 30, 2026, Minerva Neurosciences Inc reported -$290.86M of net income.
NERV net income was $100.75M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.74M a year earlier and up 476.8% from the prior quarter. For the full fiscal 2025 it was -$293.42M, compared with $1.44M in fiscal 2024.
NERV diluted EPS was -$0.19 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$34.67, compared with $0.19 in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | $0 | $41.18M | $0 | $0 | $0 | - |
| Research and development | $5.76M | $11.90M | $12.71M | $14.65M | $32.04M | $22.04M | $58.12M | $34.89M | $30.26M | $20.44M |
| Selling, general and admin | $9.34M | $9.95M | $10.41M | $10.58M | $13.33M | $17.29M | $17.74M | $16.84M | $10.91M | $9.75M |
| Operating income | -$15.10M | -$21.85M | -$23.12M | -$25.23M | -$45.37M | $1.85M | -$75.87M | -$51.73M | -$41.17M | -$30.19M |
| Pre-tax income | - | - | - | -$32.11M | -$51.71M | $1.94M | -$74.44M | -$50.17M | -$40.90M | -$31.05M |
| Income tax | - | - | - | - | -$1.80M | - | -$2.25M | $0 | -$9.40M | $0 |
| Net income | -$293.42M | $1.44M | -$30.01M | -$32.11M | -$49.91M | $1.94M | -$72.18M | -$50.17M | -$31.52M | -$31.05M |
| EPS, basic | -$34.67 | $0.19 | -$4.61 | -$6.01 | -$9.35 | $0.40 | -$14.80 | -$10.32 | -$6.64 | -$7.92 |
| EPS, diluted | -$34.67 | $0.19 | -$4.61 | -$6.01 | -$9.35 | $0.40 | -$14.80 | -$10.32 | -$6.64 | -$7.92 |
| Diluted shares | 8.5M | 7.6M | 6.5M | 5.3M | 5.3M | 5.1M | 4.9M | 4.8M | 4.7M | 3.9M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $82.30M | $21.36M | $40.91M | $36.09M | $60.76M | $25.36M | $21.41M | $50.23M | $26.05M | $83.06M |
| Short-term investments | - | - | - | - | - | - | $24.44M | $37.76M | $102.11M | - |
| Current assets | $83.10M | $22.27M | $42.00M | $40.16M | $62.20M | $27.44M | $47.14M | $90.02M | $129.54M | $83.86M |
| Goodwill | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M |
| Total assets | $97.97M | $37.14M | $56.90M | $55.09M | $77.12M | $57.63M | $77.50M | $139.14M | $183.70M | $132.94M |
| Current liabilities | $2.29M | $2.84M | $3.34M | $1.38M | $2.82M | $3.16M | $6.63M | $3.61M | $6.84M | $9.69M |
| Total liabilities | $233.76M | $62.84M | $85.36M | $75.11M | $69.15M | $4.96M | $49.72M | $48.87M | $52.10M | $26.96M |
| Shareholders' equity | -$140.75M | -$25.69M | -$28.46M | -$20.02M | $7.98M | $52.66M | $27.78M | $90.26M | $131.60M | $105.98M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.51M | -$19.55M | -$14.78M | -$24.65M | -$24.60M | -$33.82M | -$43.43M | -$41.94M | $3.09M | -$25.69M |
| Capital expenditures | - | - | - | $16.3K | - | - | - | - | $52.4K | - |
| Free cash flow | - | - | - | -$24.66M | - | - | - | - | $3.04M | - |
| Investing cash flow | $0 | $0 | $0 | -$16.3K | - | $24.53M | $14.08M | $69.49M | -$107.19M | $17.82M |
| Financing cash flow | $74.45M | - | $19.60M | -$5 | $60.00M | $13.24M | $525.0K | -$3.34M | $47.17M | $76.57M |
| Share repurchases | - | - | - | - | - | - | - | - | $389 | - |
| Stock-based compensation | $1.33M | $1.33M | $1.97M | $4.11M | $5.22M | $9.70M | $9.17M | $8.18M | $5.03M | $3.57M |
| Depreciation and amortization | $5.4K | $5.4K | $5.4K | - | - | $16.0K | $17.5K | $17.5K | $11.1K | $16.5K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | - | - | - | - | - |
| Operating margin | - | - | - | - | - | 4.5% | - | - | - | - |
| Net margin | - | - | - | - | - | 4.7% | - | - | - | - |
| Return on equity | - | - | - | - | -625.7% | 3.7% | -259.8% | -55.6% | -24.0% | -29.3% |
| Return on assets | -299.5% | 3.9% | -52.7% | -58.3% | -64.7% | 3.4% | -93.1% | -36.1% | -17.2% | -23.4% |
| Current ratio | 36.28 | 7.85 | 12.57 | 29.15 | 22.07 | 8.68 | 7.11 | 24.94 | 18.94 | 8.66 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $5.16M | $7.19M | $5.25M | $2.17M | $925.4K | $1.30M | $1.36M | $1.98M | $1.89M | $3.86M | $4.17M | $4.72M |
| Selling, general and admin | $4.28M | $3.45M | $11.42M | $2.81M | $1.92M | $2.08M | $2.54M | $2.54M | $2.48M | $2.42M | $2.51M | $2.45M |
| Operating income | -$9.43M | -$10.64M | -$16.67M | -$4.98M | -$2.84M | -$3.37M | -$3.90M | -$4.52M | -$4.37M | -$6.28M | -$6.68M | -$7.17M |
| Net income | $100.75M | $17.47M | -$125.40M | -$283.67M | -$2.74M | -$3.26M | -$3.75M | -$4.27M | $22.51M | -$8.23M | -$8.57M | -$9.02M |
| EPS, basic | $1.94 | $0.36 | -$2.86 | -$33.38 | -$0.36 | -$0.43 | -$0.50 | -$0.56 | $2.97 | -$1.09 | -$1.13 | - |
| EPS, diluted | -$0.19 | -$0.14 | -$2.86 | -$33.38 | -$0.36 | -$0.43 | -$0.50 | -$0.56 | $2.97 | -$1.09 | -$1.13 | - |
| Diluted shares | 75.3M | 79.1M | 43.9M | - | 7.6M | 7.6M | 7.6M | - | 7.6M | 7.6M | 7.6M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.22M | $24.65M | $32.66M | $82.30M | $12.29M | $15.25M | $17.29M | $21.36M | $26.53M | $30.88M | $34.82M | $40.91M |
| Short-term investments | $56.73M | $50.62M | $45.41M | - | - | - | - | - | - | - | - | - |
| Current assets | $83.41M | $79.73M | $79.11M | $83.10M | $13.02M | $15.55M | $17.92M | $22.27M | $27.94M | $31.41M | $35.62M | $42.00M |
| Goodwill | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M | $14.87M |
| Total assets | $98.28M | $95.09M | $94.03M | $97.97M | $28.09M | $30.42M | $32.80M | $37.14M | $42.81M | $46.29M | $50.51M | $56.90M |
| Current liabilities | $2.53M | $3.96M | $4.48M | $2.29M | $2.67M | $2.53M | $1.95M | $2.84M | $4.48M | $4.20M | $2.83M | $3.34M |
| Total liabilities | $184.06M | $296.65M | $343.08M | $233.76M | $62.67M | $62.53M | $61.95M | $62.84M | $64.48M | $90.78M | $87.10M | $85.36M |
| Shareholders' equity | -$97.52M | -$213.30M | -$254.01M | -$140.75M | -$34.58M | -$32.11M | -$29.15M | -$25.69M | -$21.67M | -$44.49M | -$36.59M | -$28.46M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.15M | -$13.34M | -$5.43M | -$4.48M | -$2.92M | -$2.04M | -$4.07M | -$5.17M | -$4.35M | -$3.94M | -$6.09M | -$5.99M |
| Investing cash flow | -$5.73M | -$4.83M | -$45.29M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $9.44M | $10.17M | $1.08M | $74.50M | -$45.2K | $0 | $0 | - | - | $0 | $0 | $0 |
| Stock-based compensation | $3.21M | $2.27M | $8.71M | $459.0K | $272.9K | $298.2K | $297.2K | $249.7K | $307.7K | $329.3K | $438.8K | $611.1K |
| Depreciation and amortization | - | - | - | $1.4K | $1.4K | $1.4K | $1.4K | $1.4K | $1.4K | $1.4K | $1.4K | $1.4K |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 33.02 | 20.14 | 17.65 | 36.28 | 4.87 | 6.15 | 9.21 | 7.85 | 6.23 | 7.47 | 12.58 | 12.57 |
Source: XBRL data Minerva Neurosciences Inc files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-8, first reported Nov 9, 2022.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NERV | - | - | -$290.86M | - | $125.6M |
| ALKS | $1.75B | +15.3% | -$351.0K | -0.0% | $7.76B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $17.09B |
| AXSM | $865.27M | +54.2% | -$157.29M | -18.2% | $7.05B |
| ACAD | $1.20B | +14.8% | $362.23M | 30.1% | $2.85B |